Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of
Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis
procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR)
modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy
with fludarabine and cyclophosphamide.